NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Longfellow, I have a question. Let's say we end up with 50 post 5 year survivors of whom 42 are treatment and 8 are placebo/control patients. THIS WOULD BE A RATIO OF 5:1 IN FAVOR OF TREATMENT.

We next find that 12 of the 233 treatment patients (about 5%) had the IDH mutation and that 7 of them survived past 5 years, We then know that 35 of the wild type treatment patients were alive at 5 years.

We then note that 5 of the 99 placebo/control patients had the mutation. Of those 5 controls with the mutation, 3 were post 5(+) years survivors and 2 were not. We then know that only 5 of the 99 control/placebo lived 5(+) years despite their "wild type" disadvantage.

It is easy to see that in this hypothetical example, comparing the 35 long living treatment patients without the IDH mutation (wild type) with the 5 long living wild type placebo controls, WOULD ADD UP TO A 7 FOLD ADVANTAGE IN FAVOR OF TREATMENT. This is considerable better than the 5:1 advantage in favor of treatment calculated before the IDH mutation was factored in.

Including the survival data of the patients with and without the IDH mutation may therefore be of value in shedding more light on the efficacy (or lack thereof) of the DCVax-L treatment. JMHO.